Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

VYNE Therapeutics (VYNE) EPS (Weighted Average and Diluted) (2020 - 2025)

VYNE Therapeutics' EPS (Weighted Average and Diluted) history spans 6 years, with the latest figure at -$0.13 for Q2 2025.

  • For Q2 2025, EPS (Weighted Average and Diluted) rose 40.91% year-over-year to -$0.13; the TTM value through Dec 2025 reached -$0.0, up 99.94%, while the annual FY2025 figure was -$0.63, 32.26% up from the prior year.
  • EPS (Weighted Average and Diluted) reached -$0.13 in Q2 2025 per VYNE's latest filing, up from -$0.2 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $3.88 in Q4 2023 to a low of -$14.75 in Q4 2021.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$1.46, with a median of -$0.35 recorded in 2021.
  • The largest YoY upside for EPS (Weighted Average and Diluted) was 459.52% in 2022 against a maximum downside of 1152.38% in 2022.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$14.75 in 2021, then surged by 83.73% to -$2.4 in 2022, then soared by 261.67% to $3.88 in 2023, then tumbled by 107.22% to -$0.28 in 2024, then surged by 53.57% to -$0.13 in 2025.
  • Per Business Quant, the three most recent readings for VYNE's EPS (Weighted Average and Diluted) are -$0.13 (Q2 2025), -$0.2 (Q1 2025), and -$0.28 (Q4 2024).